Klivira
Request demo

Streamlining Medicare Xtandi Prior Authorization

Navigating Medicare Xtandi prior authorization for prostate cancer treatment requires precise understanding of both federal guidelines and plan-specific requirements. Klivira automates this complex process, ensuring timely approvals and reducing administrative burden.

For revenue cycle directors and prior authorization coordinators, managing high-volume drug PAs like Xtandi (enzalutamide) under Medicare presents unique challenges. This includes distinguishing between Original Medicare's limited PA scope and the more extensive requirements of Medicare Advantage and Part D plans, each with distinct submission channels and policy criteria. Klivira provides a unified platform to address these complexities efficiently.

Understanding Xtandi (Enzalutamide) in the Medicare Context

Xtandi (enzalutamide) is an androgen receptor inhibitor prescribed for various stages of prostate cancer, including metastatic castration-resistant, non-metastatic castration-resistant, and metastatic hormone-sensitive prostate cancer. Given its critical role in oncology, Xtandi is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, necessitating robust PA management.

Original Medicare (Part A/B) Prior Authorization Pathways for Xtandi

Prior authorization for Xtandi under Original Medicare (Part A and B) is limited compared to private plans. Where medically necessary and covered under Part B (e.g., physician-administered drugs, though Xtandi is oral), submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Klivira's platform incorporates MAC-aware routing to handle per-jurisdiction submission specifics for contractors such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

Medicare Advantage and Part D Plan Requirements for Xtandi

Medicare Advantage (Part C) plans and Medicare Part D (pharmacy) plans, operated by private insurers, typically have more comprehensive prior authorization requirements for drugs like Xtandi. These plans administer PA per CMS-approved plan formularies and step-therapy protocols, which may include specific quantity limits or medical necessity criteria. Klivira integrates with these diverse payer portals and PBMs to streamline the submission and approval process for Xtandi.

Navigating National and Local Coverage Determinations

Coverage for Xtandi under Medicare is guided by National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by the responsible MACs. Adherence to these policies is critical for successful prior authorization. Klivira's NCD/LCD-aware policy logic helps ensure that submissions are aligned with the latest coverage criteria, referencing specific NCD numbers or LCD IDs, MAC jurisdiction, and effective dates.

Automating Xtandi Prior Authorizations with Klivira

Klivira's prior authorization automation platform simplifies the complex process of securing approvals for Xtandi across the Medicare landscape. By integrating with EMRs via SMART on FHIR, connecting to MAC-specific channels, and interfacing with Medicare Advantage and Part D payer portals, Klivira ensures accurate, compliant, and timely submission of X12 278 transactions and ePA requests, reducing manual effort and accelerating patient access to critical treatment.

Frequently asked questions

How does Original Medicare's prior authorization process for Xtandi differ from Medicare Advantage plans?

Original Medicare has a limited scope for prior authorization, primarily handled by MACs for medically necessary Part B services. Medicare Advantage plans, conversely, have expanded PA requirements, often including plan-specific formularies, step-therapy, and quantity limits for drugs like Xtandi, managed by private insurers.

Which entities are responsible for processing Xtandi prior authorizations under Original Medicare?

For Original Medicare, prior authorizations where applicable for Xtandi are processed by the Medicare Administrative Contractors (MACs) specific to the provider's jurisdiction. Examples include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

Are there specific coverage policies that apply to Xtandi prior authorization under Medicare?

Yes, coverage for Xtandi under Medicare is determined by National Coverage Determinations (NCDs) from CMS and Local Coverage Determinations (LCDs) published by the relevant MACs. These policies outline the medical necessity criteria that must be met for approval.

How does Klivira assist with managing Xtandi prior authorizations for Medicare Part D plans?

Klivira integrates with the systems of various Medicare Part D plans and their associated PBMs. This allows for automated submission of pharmacy prior authorization requests (ePA, NCPDP SCRIPT) for Xtandi, adherence to plan-specific formularies and step-therapy protocols, and efficient tracking of approval statuses.

What are common challenges in obtaining Medicare Xtandi prior authorization?

Challenges include navigating the distinct PA requirements of Original Medicare versus Medicare Advantage/Part D, staying current with evolving NCDs and LCDs, managing multiple submission channels (MAC portals, payer portals), and ensuring all clinical documentation supports medical necessity.

Related coverage

Other xtandi prior authorization by payer

Other xtandi prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo